BioCentury | Feb 3, 2003
Company News

Biopharm, Orquest, J&J deal

...musculoskeletal field and exclude dental and maxillofacial indications. Separately, DePuy AcroMed acquired the assets of Orquest...
...bone graft harvesting. DePuy plans to combine Healos with MP52. Biopharm GmbH , Heidelberg, Germany Orquest Inc....
BioCentury | Oct 16, 2000
Company News

Orquest, Sulzer Medica sales and marketing update

...SMEN launched Orquest's Healos Bone Graft Substitute in the EU. Healos, a synthetic autograft substitute made...
...minerals, is used to decrease surgical time and post-operative complications associated with spine fusion surgery. Orquest Inc....
BioCentury | Jun 5, 2000
Company News

Orquest management update

Orquest Inc. , Mountain View, Calif. Business: Biomaterial/Skin/Wound Hired: Gregory Casciaro as president and CEO, formerly president and CEO of General Surgical Innovations Inc. WIR Staff...
BioCentury | Apr 10, 2000
Company News

Biopharm, Orquest deal

...fracture, dental and cartilage repair. Biopharm will contribute its MP52 recombinant BMP growth factor, and Orquest...
...growth factors and matrices. The companies previously agreed to develop HealosMP52 for spinal fusion with Orquest...
...partner Sulzer Spine-Tech (Minneapolis, Minn.) (see BioCentury, Oct. 4, 1999). Biopharm GmbH , Heidelberg, Germany Orquest Inc....
BioCentury | Jan 17, 2000
Clinical News

Healos Bone Graft Substitute: Testing Update

Orquest Inc. , Mountain View, Calif. Product: Healos Bone Graft Substitute Business: Musculoskeletal Therapeutic category: Tissue replacement Target: NA Description: Mineralized collagen Indication: Stabilize the spine during spinal fusion Status: Partner Sulzer Medica's Sulzer Spine-Tech subsidiary...
BioCentury | Oct 4, 1999
Company News

Biopharm, Orquest, Sulzer Medica deal

...Biopharm and Orquest will develop Healos/MP52, a bone growth factor product to treat spinal disorders. The...
...spinal disorders. The product will be based on Biopharm's MP52 recombinant bone inducing cytokine and Orquest's...
...from Sulzer Spine-Tech and will manufacture the product for Sulzer. Biopharm GmbH , Heidelberg, Germany Orquest Inc....
BioCentury | Nov 2, 1998
Clinical News

Orquest preclinical data

...grafting techniques. Data were presented at the North American Spine Society meeting in San Francisco. Orquest Inc....
BioCentury | Oct 5, 1998
Clinical News

Orquest preclinical data

...The product is in performance clinical trials in Europe and feasibility testing in the U.S. Orquest Inc....
BioCentury | May 11, 1998
Company News

Orquest other research news

...development of materials to help regenerate the cartilage on the surface of bones at joints. Orquest Inc....
BioCentury | May 11, 1998
Company News

Orquest management update

Orquest Inc., Mountain View, Calif. Business: Biomaterial/Skin/Wound, Musculoskeletal Hired: Shirley Clayton as VP of finance and CFO, formerly president and CEO of Topometrix WIR Staff Dermatology Musculoskeletal...
Items per page:
1 - 10 of 16
BioCentury | Feb 3, 2003
Company News

Biopharm, Orquest, J&J deal

...musculoskeletal field and exclude dental and maxillofacial indications. Separately, DePuy AcroMed acquired the assets of Orquest...
...bone graft harvesting. DePuy plans to combine Healos with MP52. Biopharm GmbH , Heidelberg, Germany Orquest Inc....
BioCentury | Oct 16, 2000
Company News

Orquest, Sulzer Medica sales and marketing update

...SMEN launched Orquest's Healos Bone Graft Substitute in the EU. Healos, a synthetic autograft substitute made...
...minerals, is used to decrease surgical time and post-operative complications associated with spine fusion surgery. Orquest Inc....
BioCentury | Jun 5, 2000
Company News

Orquest management update

Orquest Inc. , Mountain View, Calif. Business: Biomaterial/Skin/Wound Hired: Gregory Casciaro as president and CEO, formerly president and CEO of General Surgical Innovations Inc. WIR Staff...
BioCentury | Apr 10, 2000
Company News

Biopharm, Orquest deal

...fracture, dental and cartilage repair. Biopharm will contribute its MP52 recombinant BMP growth factor, and Orquest...
...growth factors and matrices. The companies previously agreed to develop HealosMP52 for spinal fusion with Orquest...
...partner Sulzer Spine-Tech (Minneapolis, Minn.) (see BioCentury, Oct. 4, 1999). Biopharm GmbH , Heidelberg, Germany Orquest Inc....
BioCentury | Jan 17, 2000
Clinical News

Healos Bone Graft Substitute: Testing Update

Orquest Inc. , Mountain View, Calif. Product: Healos Bone Graft Substitute Business: Musculoskeletal Therapeutic category: Tissue replacement Target: NA Description: Mineralized collagen Indication: Stabilize the spine during spinal fusion Status: Partner Sulzer Medica's Sulzer Spine-Tech subsidiary...
BioCentury | Oct 4, 1999
Company News

Biopharm, Orquest, Sulzer Medica deal

...Biopharm and Orquest will develop Healos/MP52, a bone growth factor product to treat spinal disorders. The...
...spinal disorders. The product will be based on Biopharm's MP52 recombinant bone inducing cytokine and Orquest's...
...from Sulzer Spine-Tech and will manufacture the product for Sulzer. Biopharm GmbH , Heidelberg, Germany Orquest Inc....
BioCentury | Nov 2, 1998
Clinical News

Orquest preclinical data

...grafting techniques. Data were presented at the North American Spine Society meeting in San Francisco. Orquest Inc....
BioCentury | Oct 5, 1998
Clinical News

Orquest preclinical data

...The product is in performance clinical trials in Europe and feasibility testing in the U.S. Orquest Inc....
BioCentury | May 11, 1998
Company News

Orquest other research news

...development of materials to help regenerate the cartilage on the surface of bones at joints. Orquest Inc....
BioCentury | May 11, 1998
Company News

Orquest management update

Orquest Inc., Mountain View, Calif. Business: Biomaterial/Skin/Wound, Musculoskeletal Hired: Shirley Clayton as VP of finance and CFO, formerly president and CEO of Topometrix WIR Staff Dermatology Musculoskeletal...
Items per page:
1 - 10 of 16